Login to Your Account

Translarna dharma? Bid in doubt after Biomarin's Kyndrisa no-surprise CRL

By Randy Osborne
Staff Writer

Thursday, January 14, 2016

While the marketing application in Europe remains under review, U.S. regulators' complete response letter (CRL) to Biomarin Pharmaceutical Inc. for Kyndrisa in DMD hardly stirred company backers, given the negative advisory committee (adcom) meeting in November.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription